clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yeh I et al. | Cutaneous mycobacterial spindle cell pseudotumor: a potential mimic of soft tissue neoplasms. | 2011 | Am J Dermatopathol | pmid:21712686 |
| Song H et al. | Cutaneous nontuberculous mycobacterial infection: a clinicopathological study of 7 cases. | 2009 | Am J Dermatopathol | pmid:19384062 |
| Lai J et al. | Epithelioid histiocytic infiltrate caused by Mycobacterium scrofulaceum infection: a potential mimic of various neoplastic entities. | 2013 | Am J Dermatopathol | pmid:22935892 |
| Sketris IS et al. | Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies. | 2004 | Am J Geriatr Pharmacother | pmid:15555476 |
| Hsu O et al. | Decreased plasma efavirenz concentrations in a patient receiving rifabutin. | 2010 | Am J Health Syst Pharm | pmid:20852162 |
| Johnson TJ and Hedge DD | Esomeprazole: a clinical review. | 2002 | Am J Health Syst Pharm | pmid:12132559 |
| Halpern MT et al. | Cost-effectiveness of gemifloxacin: results from the GLOBE study. | 2002 | Am J Health Syst Pharm | pmid:12132563 |
| Chahine C et al. | Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori. | 2001 | Am J Health Syst Pharm | pmid:11596697 |
| Henneman A and Thornby KA | Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics. | 2012 | Am J Health Syst Pharm | pmid:22644980 |
| Kaeser YA et al. | Severe hypotension and bradycardia associated with verapamil and clarithromycin. | 1998 | Am J Health Syst Pharm | pmid:9825040 |
| Three new studies expand understanding of MAC therapy. | 1996 | Am J Health Syst Pharm | pmid:8899122 | |
| Peloquin CA and Berning SE | Advice on treatment of Mycobacterium avium complex infection. | 1997 | Am J Health Syst Pharm | pmid:9161632 |
| H. pylori treatment recognized by FDA. | 1996 | Am J Health Syst Pharm | pmid:8725200 | |
| Sonnenberg A et al. | Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. | 1999 | Am J Manag Care | pmid:10345967 |
| Lilley LL and Guanci R | A dangerous combination. | 1998 | Am J Nurs | pmid:9612423 |
| Antibiotic gets FDA nod for MAC treatment. | 1994 | Am J Nurs | pmid:8304386 | |
| Evans AK and Cunningham MJ | Atypical mycobacterial cervicofacial lymphadenitis in children: a disease as old as mankind, yet a persistent challenge. | 2005 Sep-Oct | Am J Otolaryngol | pmid:16137534 |
| Hashisaki GT | Update on macrolide antibiotics. | 1995 May-Jun | Am J Otolaryngol | pmid:7661309 |
| Einarson A et al. | A prospective controlled multicentre study of clarithromycin in pregnancy. | 1998 | Am J Perinatol | pmid:9890248 |
| Jacoby EB and Porter KB | Helicobacter pylori infection and persistent hyperemesis gravidarum. | 1999 | Am J Perinatol | pmid:10355915 |
| Abouesh A and Hobbs WR | Clarithromycin-induced mania. | 1998 | Am J Psychiatry | pmid:9812131 |
| Brooks JO and Hoblyn JC | Secondary mania in older adults. | 2005 | Am J Psychiatry | pmid:16263839 |
| Keicho N and Kudoh S | Diffuse panbronchiolitis: role of macrolides in therapy. | 2002 | Am J Respir Med | pmid:14720066 |
| Darkes MJ and Perry CM | Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. | 2003 | Am J Respir Med | pmid:14720016 |
| Tohnai A et al. | Clarithromycin suppresses proliferation of rat nasal epithelium exposed to endotoxin. | 1998 Nov-Dec | Am J Rhinol | pmid:9883303 |
| Zeng M et al. | Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. | 2011 Nov-Dec | Am J Rhinol Allergy | pmid:22185725 |
| Gupta AK and Moorman CT | Nocardia nova infection after primary anterior cruciate ligament reconstruction with tibialis anterior allograft. | 2010 | Am J Sports Med | pmid:20375367 |
| Yang X et al. | Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. | Am J Ther | pmid:25923229 | |
| Feng L et al. | Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. | Am J Ther | pmid:25569598 | |
| McCarthy DM et al. | Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. | 2003 Sep-Oct | Am J Ther | pmid:12975717 |
| Chang NL et al. | Clarithromycin-Induced Torsades de Pointes. | Am J Ther | pmid:25057773 | |
| Kurowski K et al. | Clarithromycin-induced alterations in vaginal flora. | 2000 | Am J Ther | pmid:11317173 |
| Alkim H et al. | Role of Bismuth in the Eradication of Helicobacter pylori. | Am J Ther | pmid:26808355 | |
| Jacobson TA | Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. | 2004 | Am. J. Cardiol. | pmid:15518608 |
| Hsu CH et al. | The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients. | 2006 | Am. J. Chin. Med. | pmid:17163582 |
| Wang YC et al. | In vitro activity of Impatiens balsamina L. against multiple antibiotic-resistant Helicobacter pylori. | 2009 | Am. J. Chin. Med. | pmid:19655409 |
| Sauter C and Blum S | Regression of lung lesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease. | 2003 | Am. J. Clin. Oncol. | pmid:12576932 |
| Kapadia M et al. | Invasive Streptomyces infections: six cases and literature review. | 2007 | Am. J. Clin. Pathol. | pmid:17369139 |
| Buchanan Keller K and Lemberg L | Torsade. | 2008 | Am. J. Crit. Care | pmid:18158394 |
| Gisbert JP et al. | Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? | 2005 | Am. J. Gastroenterol. | pmid:16128936 |
| Mohar A et al. | Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. | 2002 | Am. J. Gastroenterol. | pmid:12385434 |
| De Francesco V et al. | Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? | 2002 | Am. J. Gastroenterol. | pmid:12385470 |
| Cremonini F et al. | Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. | 2002 | Am. J. Gastroenterol. | pmid:12425542 |
| Nista EC et al. | Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. | 2006 | Am. J. Gastroenterol. | pmid:16968503 |
| van Zanten SV and Thompson K | Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? | 2006 | Am. J. Gastroenterol. | pmid:16863548 |
| Watson JB and Moss SF | Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. | 2011 | Am. J. Gastroenterol. | pmid:22056576 |
| Hsu PI et al. | A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. | 2005 | Am. J. Gastroenterol. | pmid:16279889 |
| Dohil R et al. | Effective 2-wk therapy for Helicobacter pylori disease in children. | 1997 | Am. J. Gastroenterol. | pmid:9040199 |
| Lerang F et al. | Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? | 1997 | Am. J. Gastroenterol. | pmid:9040200 |
| Trevisani L et al. | A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. | 1998 | Am. J. Gastroenterol. | pmid:9517646 |